1Hadziyannis S J, Papatheodoridis GV. Adefovir dipivoxil in the treatment of chronic hepatitis B virus infection. Expert Rev Anti Infect Ther,2004,2 : 475-483.
2Vassiliadis T, Nikolaidis N, Giouleme O, et al. Adefovir dipivoxil added to ongoing lamivudine therapy in patients with lamivudine-resistant hepatitis B e antigen-negative chronic hepatitis B. Aliment Pharmacol Ther,2005,21:531-537.
3Lampertieo P, Vigano P, Manenti E, et al. Adefovir rapidly suppresses hepatitis B in HBeAg negative patients developing gen otypic resistance to lamivudine. Hepatology,2005,42:1414-1419.
4Rapti I, Dimou E, Mitsoula P,et al. Adding on versus switching to adefovir tehrapy in lamivudine resistant HBeAg-negative chronic hepatitis B, Hepatology,2007,45:307-313.
5Keeffe EB, Dieterieh DT, Han SHB, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. Clin Gastroenterol Hepatol, 2006,4: 936-962.
6Stoop JN, van der Molen RG, Baan CC,et al. Regulatory T ceils contribute to the lint)aired immune response in patients with chronic hepatitis B virus infection. Hepatology,2005, 41 : 771-778.
同被引文献13
1Liaw Y-F,Gane E,Leung N,et al.2-Year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B.Gastroenterology,2009,136:486-495.
2Gaeta GB,Stornaiuolo G.Therapy of chronic hepatitis B:focus on telbivudine.Dig Liver Dis,2007,39(Suppl 3):S372-S378.
3Wursthorn K,Jung M,Riva A,et al.Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen-positive patients.H epatology,2010,52:1611- 1120.
4Cai W,Xie Q,An B,et al.On-treatment serum HBsAg level is predictive of sustained off-treatment virologic response to telbivudine in HBeAg-positive chronic hepatitis B patients.J Clin Virol,2010,48:22-26.
5Keeffe EB,Dieterich DT,Han SHB,et al.A treatment algorithm for the management of chronic hepatitis B virus infection in the United States:an update.Clin Gastroenterol Hepatol,2006,4: 936-962.
6Zeuzem S,Gane E,Liaw YF,et al.Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B.J Hepatol,2009,51: 11-20.
